z-logo
Premium
miR‐452 promotes cell metastasis and the epithelial to mesenchymal by targeting SOX7 in clear‐cell renal‐cell carcinoma
Author(s) -
Liu Feng,
Guo Lihua,
Xin Guangda,
Wang Zhixin
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.28125
Subject(s) - clear cell renal cell carcinoma , downregulation and upregulation , cancer research , cell growth , cell , western blot , metastasis , biology , renal cell carcinoma , medicine , pathology , cancer , gene , biochemistry , genetics
Abstract Clear‐cell renal‐cell carcinoma (ccRCC) is the most common renal cell carcinoma (RCC), representing 75%‐80% of the cases of RCC, and characterized by a high recurrence rate and poor prognosis. miR‐452 acts as a tumor promoter in several tumors, including ccRCC. The purpose of this study was to determine the role of miR‐452 in ccRCC. miR‐452 and SOX7 messenger RNA and protein levels were calculated by quantitative reverse transcription polymerase chain reaction and Western blot analysis. MTT and Transwell assays were utilized to measure proliferative and invasive abilities. The Kaplan‐Meier method was used to evaluate the association between the expression of miR‐452 or SOX7 and the overall survival of ccRCC patients. Our results showed that miR‐452 was overexpressed in ccRCC tissues and cells, and upregulation of miR‐452 predicted a poor 5‐year survival in ccRCC patients. In contrast, expression of SOX7 was low and downregulation of SOX7 predicted poor prognosis in ccRCC. In addition, miR‐452 promoted cell proliferation, invasion, and the EMT, while SOX7 reversed the function of miR‐452 on cell proliferation and invasion in 786‐O cells. In conclusion, miR‐452 was shown to inhibit cell proliferation, invasion, and the EMT through SOX7 in ccRCC, and the newly identified miR‐452 / SOX7 axis provided novel insight into the pathogenesis of ccRCC.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here